Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary
- PMID: 30515910
- PMCID: PMC6718007
- DOI: 10.1002/pds.4697
Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary
References
-
- Energy and Commerce Committee . 21st Century Cures Act. Retrieved 01OCT 2018 https://energycommerce.house.gov/cures
-
- Center for drug evaluation and research. Prescription Drug User Fee Act (PDUFA)—PDUFA VI: fiscal years 2018–2022. U.S. Food and Drug Administration. Retrieved 01 October 2018. http://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm44660...
-
- U.S. Food and Drug Administration . Use of real‐world evidence to support regulatory decision‐making for medical devices. Guidance for Industry and Food and Drug Administration staff. Center for Devices and Radiological Health (CDRH). Retrieved 12 October 2018. https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance...
-
- Berger, M , Daniel, G , Frank, K , et al. A framework for regulatory use of real world evidence. Retrieved 06SEPT2017. https://healthpolicy.duke.edu/sites/default/files/atoms/files/rwe_white_...
MeSH terms
LinkOut - more resources
Full Text Sources
